First-in-Class Oral Treatment for LN: Lupkynis (voclosporin) was the first FDA-approved oral calcineurin inhibitor specifically for the treatment of adult patients with active lupus nephritis, providing a novel and targeted therapy option.

Proven Clinical Efficacy: Pivotal clinical trials (AURORA 1 and 2) demonstrated superior renal response rates and a significant reduction in proteinuria compared to standard of care, establishing strong evidence of its therapeutic benefit.

Addresses Significant Unmet Medical Need: Lupus nephritis is a severe autoimmune disease with a high risk of kidney failure, and Lupkynis provides a much-needed, effective treatment option where existing therapies were often insufficient or associated with severe side effects.